Literature DB >> 2407652

Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid.

T Lagergard1, J Shiloach, J B Robbins, R Schneerson.   

Abstract

A synthetic scheme for covalently binding group B streptococcus type III to tetanus toxoid (TT), using adipic acid dihydrazide as a spacer, is described. Type III alone or as a conjugate with TT was injected subcutaneously into laboratory mice, and the type-specific and TT antibody responses elicited by these immunogens were assayed. Type III-TT elicited significantly higher levels of type-specific antibodies after each immunization than did the type III alone. These levels were related to the dosage of the conjugate, enhanced by Freund adjuvant, and exhibited booster responses. Type III alone elicited only immunoglobulin M (IgM) antibodies in Swiss albino mice and mostly IgM and low levels of IgG antibodies of the IgG3 subclass in BALB/c mice. Type III-TT conjugates, in contrast, elicited mostly IgG antibodies in both strains of mice. IgA type III antibodies were not detected. The first two immunizations with the conjugates elicited type III antibodies in the IgG1 and in the IgG3 subclasses. Low levels of IgG2a type III antibodies were detected after a third injection of type III-TT. Conjugate-induced antibodies facilitated opsonization of group B streptococcus type III organisms and did not react with the structurally related pneumococcus type 14. TT alone or as a component of type III-TT induced mostly antibodies of the IgG class: IgG1 levels were the highest of the four subclasses. No IgA TT antibodies were detected. The conjugation procedure, therefore, enhanced the immunogenicity of and conferred T-cell dependent properties to the type III while preserving the immunogenicity of the TT component. The T-cell dependent properties of the conjugates were responsible for stimulating IgG type III antibodies which could be boosted. Evaluation of type III-TT conjugates in antibody-negative women of child-bearing age is planned.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2407652      PMCID: PMC258520          DOI: 10.1128/iai.58.3.687-694.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  52 in total

1.  Group B streptococcal neonatal and infant infections.

Authors:  R A Franciosi; J D Knostman; R A Zimmerman
Journal:  J Pediatr       Date:  1973-04       Impact factor: 4.406

2.  Opsonic specificity of human antibody to the type III polysaccharide of group B Streptococcus.

Authors:  M S Edwards; C J Baker; D L Kasper
Journal:  J Infect Dis       Date:  1979-12       Impact factor: 5.226

3.  Suppurative meningitis due to streptococci of Lancefield group B: a study of 33 infants.

Authors:  C J Baker; F F Barrett; R C Gordon; M D Yow
Journal:  J Pediatr       Date:  1973-04       Impact factor: 4.406

4.  Structural determination of the capsular polysaccharide antigen of type II group B Streptococcus.

Authors:  H J Jennings; K G Rosell; E Katzenellenbogen; D L Kasper
Journal:  J Biol Chem       Date:  1983-02-10       Impact factor: 5.157

5.  Structure of native polysaccharide antigens of type Ia and type Ib group B Streptococcus.

Authors:  H J Jennings; E Katzenellenbogen; C Lugowski; D L Kasper
Journal:  Biochemistry       Date:  1983-03-01       Impact factor: 3.162

6.  Group B streptococcal carriage and disease: a 6-year prospective study.

Authors:  H C Dillon; S Khare; B M Gray
Journal:  J Pediatr       Date:  1987-01       Impact factor: 4.406

7.  Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates.

Authors:  R Schneerson; J B Robbins; J C Parke; C Bell; J J Schlesselman; A Sutton; Z Wang; G Schiffman; A Karpas; J Shiloach
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

8.  Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates.

Authors:  C Chu; R Schneerson; J B Robbins; S C Rastogi
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

9.  Conformational aspects critical to the immunospecificity of the type III group B streptococcal polysaccharide.

Authors:  H J Jennings; C Lugowski; D L Kasper
Journal:  Biochemistry       Date:  1981-08-04       Impact factor: 3.162

10.  Isolation and characterization of type IV group B Streptococcus capsular polysaccharide.

Authors:  M R Wessels; W J Benedí; H J Jennings; F Michon; J L DiFabio; D L Kasper
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

View more
  25 in total

1.  Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine.

Authors:  X Shen; T Lagergård; Y Yang; M Lindblad; M Fredriksson; J Holmgren
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

2.  Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy.

Authors:  M R Wessels; L C Paoletti; H K Guttormsen; F Michon; A J D'Ambra; D L Kasper
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

3.  Mucosal memory B cells retain the ability to produce IgM antibodies 2 years after oral immunization.

Authors:  M Vajdy; N Lycke
Journal:  Immunology       Date:  1995-11       Impact factor: 7.397

4.  Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.

Authors:  M R Wessels; L C Paoletti; D L Kasper; J L DiFabio; F Michon; K Holme; H J Jennings
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

5.  Structurally defined epitopes of Haemophilus ducreyi lipooligosaccharides recognized by monoclonal antibodies.

Authors:  H J Ahmed; A Frisk; J E Månsson; E K Schweda; T Lagergård
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

6.  Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.

Authors:  L C Paoletti; M R Wessels; A K Rodewald; A A Shroff; H J Jennings; D L Kasper
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

7.  Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine.

Authors:  M R Wessels; L C Paoletti; A K Rodewald; F Michon; J DiFabio; H J Jennings; D L Kasper
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

8.  Antibodies to poly[(2----8)-alpha-N-acetylneuraminic acid] and poly[(2----9)-alpha-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1.

Authors:  S J Devi; J B Robbins; R Schneerson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

9.  Isotype composition of antibodies to streptococcus group B type III polysaccharide and to tetanus toxoid in maternal, cord blood sera and in breast milk.

Authors:  T Lagergård; K Thiringer; L Wassén; R Schneerson; B Trollfors
Journal:  Eur J Pediatr       Date:  1992-02       Impact factor: 3.183

10.  Immunogenicity of Vibrio vulnificus capsular polysaccharides and polysaccharide-protein conjugates.

Authors:  J G Simonson; R J Siebeling
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.